Regeneron Pharmaceuticals Aktie

504,60 EUR -3,00 EUR -0,59 %

19.09.2025

BMN

594,86 USD +2,01 USD +0,34 %

nachbörslich20.09.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.53,42 Mrd. EUR

KGV18,58Div. Rendite0,00%

WKN881535

ISINUS75886F1075

SymbolREGN

Regeneron Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

08.01.24PR NewswireMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

17.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

19.05.23PR NewswireHigh School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023

15.03.23PR NewswireStudents Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

24.01.23PR NewswireTop 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition

23.12.22PR NewswireLibtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer

21.12.22PR NewswirePositive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine

19.12.22PR NewswireRegeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

16.12.22PR NewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis

15.12.22PR NewswireDupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis

12.12.22PR NewswireOdronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial

12.12.22PR NewswireLinvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma

12.12.22PR NewswireRegeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year

11.12.22PR NewswirePivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH

01.12.22PR NewswireRegeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types

30.11.22PR NewswireEvkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review

25.11.22RSSForm 4 872589

22.11.22PR NewswireLibtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology

17.11.22PR NewswireRegeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

11.11.22PR NewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

10.11.22RSSForm 4 872589

08.11.22PR NewswireLibtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)

05.11.22PR NewswireAflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration

03.11.22PR NewswireRegeneron Announces Investor Conference Presentations

03.11.22PR NewswireRegeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders

03.11.22PR NewswireRegeneron Reports Third Quarter 2022 Financial and Operating Results

03.11.22RSSForm 8-K 872589

03.11.22RSSForm 10-Q 872589

02.11.22RSSForm 4 872589

28.10.22PR NewswireInmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award

21.10.22PR NewswireRegeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection

14.10.22PR NewswireLibtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer

12.10.22PR NewswireEYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review

11.10.22PR NewswireDupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old

04.10.22PR NewswireRegeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022

03.10.22PR NewswireRegeneron Elects Dr. Craig B. Thompson to Board of Directors

30.09.22PR NewswireAflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO

28.09.22PR NewswireDupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

Regeneron Pharmaceuticals News

Regeneron Pharmaceuticals News: auf dieser Seite finden Sie alle Regeneron Pharmaceuticals News und Nachrichten zur Regeneron Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Regeneron Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Regeneron Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.